Si terrà a Los Angeles dal 5 al 7 febbraio l’edizione 2025 dell’International Stroke Conference, il meeting annuale dell’American Stroke Association che riunisce esperti di tutto il mondo per discutere le ultime ricerche e le migliori pratiche nella cura dell’ictus. Le sessioni pre-congressuali si svolgeranno il 5 febbraio e copriranno argomenti come la riabilitazione dell’ictus, la prevenzione dell’ictus e l’ictus ischemico. Le sessioni principali si svolgeranno invece dal 6 al 7 febbraio e copriranno una vasta gamma di argomenti, tra cui la gestione dell’ictus, la terapia trombolitica e i progressi nella ricerca sull’ictus.
Di seguito riportiamo l’elenco delle Late-Breaking Science Main Event Sessions:
Giovedì 5 febbraio:
- MIND – LB1: Procedural, safety, and functional outcomes following minimally invasive surgery for deep and lobar intracranial hemorrhages: MIND study results.
- TRACE – LB2: TransRadial versus transfemoral Arterial access for CErebral angiography.
- DISTAL – LB3: Endovascular therapy plus best medical treatment versus best medical treatment alone for medium distal vessel occlusion stroke.
- ESCAPE-MeVO – LB4: Endovascular treatment to improve outcomes for medium vessel occlusions: The ESCAPE-MeVO trial.
- DISCOUNT – LB47: Mechanical Thrombectomy in Acute Ischemic Stroke Related to a Distal Arterial Occlusion: Interim Analysis of the DISCOUNT Randomized Controlled Trial.
Venerdì 6 febbraio:
- TRANSPORT2 – LB16: TRANScranial direct current stimulation for POst-stroke motor Recovery – a phase II sTudy (TRANSPORT2) – Main Results.
- LB17: Intensive Blood Pressure Lowering After Thrombectomy in Ischemic Stroke Patients-A Randomized Clinical Trial.
- C3FIT – LB18: Coordinated, Collaborative, Comprehensive, Family-based, Integrated, Technology-enabled Post-Stroke Care.
- ICH-ADAPT – LB19: The Intracerebral Hemorrhage acutely decreasing arterial pressure trial II Final Results.
- LB20: Atorvastatin Treatment and Rebleeding in Cerebral Cavernous Malformations: A Randomized, Placebo-Controlled, Double-Blinded Clinical Trial.
Sabato 7 febbraio:
- PRESTIGE-AF – LB37: Effects of Direct Oral Anticoagulants Versus No Anticoagulation In the Prevention of Stroke in Intracerebral Haemorrhage Survivors with Atrial Fibrillation (PRESTIGE-AF) Trial.
- ANGEL-TNK – LB38: Intra-arterial Tenecteplase thrombolysis for acute LVO after successful mechanical thrombectomy recanalization (ANGEL-TNK) — A Multicenter, Prospective, Randomized, Open-label, Blinded End-point Trial.
- DATE – LB39: The Optimal Dosage of ADjunctive Intra-Arterial Tenecteplase following Successful Endovascular Thrombectomy in Patients with Large Vessel Occlusion Acute Ischemic Stroke (DATE) Trail.
- ETERNAL-LVO – LB40: Extending the Time Window for Tenecteplase by Effective Reperfusion of Penumbral Tissue in Patients with Large Vessel Occlusion (ETERNAL-LVO): a multicentre, prospective, open-label, blinded endpoint, controlled, phase III, superiority trial.
- HOPE – LB41: Treatment with intravenous alteplase in ischemic stroke patients with onset time between 4.5 and 24 hours.
- PEARL – LB42: Intra-arterial Alteplase for Acute Ischemic Stroke After Mechanical Thrombectomy (PEARL): A Multicenter Randomized Trial.
- ATIS-NVAF – LB43: A randomized controlled trial of antithrombotic therapy in ischemic stroke patients with non-valvular atrial fibrillation and atherosclerosis: The ATIS-NVAF trial.
- LAMP – LB44: Liraglutide in Acute Minor Ischemic Stroke or High-risk Transient Ischemic Attack Patients with Type 2 Diabetes Mellitus (LAMP): A Randomized Clinical Trial.
- BEST – LB45: BXOS110 for Acute Ischemic Stroke Treatment (BEST): A Multicenter, Double-Blind, Randomized, Placebo-Controlled, Phase 2 Trial.
